Pharmaceutical Technology

MAY 2, 2023

IO agents include the classes of immune checkpoint modulators, cell therapies, bispecific antibodies, oncolytic viruses, therapeutic vaccines, and cytokines. All currently approved CAR-Ts are autologous, with the patient’s T-cells being genetically engineered to target antigens expressed by the cancerous cells.

Immunization 52

Immunization Vaccines 52

pharmaphorum

APRIL 5, 2022

Immunocore now has approval on both side of the Atlantic for Kimmtrak – the first cancer therapeutic based on T cell receptor (TCR) technology – after getting a green light from the European Commission. It’s the first treatment for mUM in the EU, as well as the first BiTE drug to treat a solid tumour.

Labelling 52

Labelling Chemotherapy Immunization 52

Pharmaceutical Technology

APRIL 5, 2023

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. Currently, all approved CAR-T therapies are autologous, where T cells taken from patients are modified and then re-infused. BL: The ISCT engages with professionals in 65 countries.

FDA 59

FDA Immunization 59

Pharmaceutical Technology

FEBRUARY 10, 2023

This is not the first treatment to come with a high price tag. Using this categorization, programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors saw the greatest percentage of RSAs granted. million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

FDA 105

FDA 105

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Immunization Vaccines 52

European Pharmaceutical Review

NOVEMBER 10, 2022

Target engagement (efficacy) – cellular uptake and cytoplasmic/nuclear delivery of cargo is a major bottleneck for clinical translation. Figure 2 : Super-resolution imaging of CRISPR/Cas9 reporter cell lines enables visualisation of cellular uptake of complex medicines. Figure 2 ). Challenges .

Labelling 97

Labelling Compounding 97

Roots Analysis

AUGUST 28, 2022

Recent advances in multi-omics approaches, including genomics, transcriptomics, proteomics, metabolomics, cytometry and imaging, in combination with bioinformatics and biostatistics, have been translated into several popular bioanalytical platforms, such as next-generation sequencing (NGS), single-cell analysis, flow cytometry and mass spectrometry.

52

52